Multicenter extension and switch study evaluating the safety of long-term treatment with abiraterone acetate fine particle formulation (AAFP) in patients with metastatic castration-resistant prostate cancer (mCRPC): The STAAR-E study.
Levin R, Given R, Nemeth P, Bosch B, Chapas-Reed J, Oh W. Multicenter extension and switch study evaluating the safety of long-term treatment with abiraterone acetate fine particle formulation (AAFP) in patients with metastatic castration-resistant prostate cancer (mCRPC): The STAAR-E study. Journal Of Clinical Oncology 2018, 36: 181-181. DOI: 10.1200/jco.2018.36.6_suppl.181.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerAdverse eventsSafety of long-term treatmentCastration-resistant prostate cancerExtension studyClinical laboratory test resultsLong-term treatmentLonger-term treatmentDays of treatmentPSA levelsAbiraterone acetateBilirubin increasePrednisone treatmentMedian ageProstate cancerProgressive diseaseSafety profileSerum testosteroneMethylprednisoloneTreatment durationLiver enzymesPrior treatmentPrednisonePatientsLaboratory test results
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply